Wooridul Huebrain Limited (118000.KS)
KRW 316.0
(-1.25%)
KRW 316.0
(-1.25%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.87 Billion KRW | 28.91% |
| 2022 | -27.67 Billion KRW | -1278.43% |
| 2021 | 18.38 Billion KRW | -134.25% |
| 2020 | 14.07 Billion KRW | 110.9% |
| 2019 | 1.22 Billion KRW | 116.3% |
| 2018 | -9.54 Billion KRW | -98.33% |
| 2017 | -1.23 Billion KRW | 44.81% |
| 2016 | -5.62 Billion KRW | 16.73% |
| 2015 | -6.34 Billion KRW | -32.91% |
| 2014 | -7.52 Billion KRW | -80.97% |
| 2013 | -3.22 Billion KRW | 40.22% |
| 2012 | -2.93 Billion KRW | 34.9% |
| 2011 | -5.43 Billion KRW | -3337.77% |
| 2010 | 920.03 Million KRW | -62.07% |
| 2009 | 336.6 Million KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.82 Billion KRW | 168.32% |
| 2024 Q2 | 680.38 Million KRW | -95.23% |
| 2023 FY | - KRW | 28.91% |
| 2023 Q2 | 1.04 Billion KRW | -26.58% |
| 2023 Q1 | 1.42 Billion KRW | 112.44% |
| 2023 Q4 | -6.29 Billion KRW | -495.97% |
| 2023 Q3 | 1.59 Billion KRW | 51.98% |
| 2022 FY | - KRW | -1278.43% |
| 2022 Q2 | 2.1 Billion KRW | 543.48% |
| 2022 Q1 | -474.62 Million KRW | 54.16% |
| 2022 Q3 | 449.54 Million KRW | -78.64% |
| 2022 Q4 | -11.46 Billion KRW | -2649.47% |
| 2021 Q3 | 920.2 Million KRW | -37.48% |
| 2021 Q1 | -2.22 Billion KRW | -191.03% |
| 2021 FY | - KRW | -134.25% |
| 2021 Q2 | 1.47 Billion KRW | 166.27% |
| 2021 Q4 | -1.03 Billion KRW | -212.53% |
| 2020 Q4 | 2.43 Billion KRW | 4279.91% |
| 2020 Q2 | 181.42 Million KRW | 126.53% |
| 2020 Q1 | -683.87 Million KRW | -133.03% |
| 2020 FY | - KRW | 110.9% |
| 2020 Q3 | 55.7 Million KRW | -69.3% |
| 2019 Q1 | -589.96 Million KRW | 56.45% |
| 2019 FY | - KRW | 116.3% |
| 2019 Q3 | -191.75 Million KRW | 68.88% |
| 2019 Q4 | 2.07 Billion KRW | 1179.88% |
| 2019 Q2 | -616.07 Million KRW | -4.43% |
| 2018 Q1 | -1.44 Billion KRW | -223.37% |
| 2018 Q4 | -1.35 Billion KRW | -9.72% |
| 2018 Q3 | -1.23 Billion KRW | -111.54% |
| 2018 FY | - KRW | -98.33% |
| 2018 Q2 | -583.58 Million KRW | 59.71% |
| 2017 FY | - KRW | 44.81% |
| 2017 Q2 | -1.87 Billion KRW | -190.55% |
| 2017 Q3 | -1.96 Billion KRW | -4.62% |
| 2017 Q4 | 1.17 Billion KRW | 159.84% |
| 2017 Q1 | -645.45 Million KRW | 71.72% |
| 2016 Q1 | -1.07 Billion KRW | 0.38% |
| 2016 FY | - KRW | 16.73% |
| 2016 Q4 | -2.28 Billion KRW | -141.01% |
| 2016 Q3 | -946.86 Million KRW | 12.31% |
| 2016 Q2 | -1.07 Billion KRW | -0.67% |
| 2015 Q4 | -1.07 Billion KRW | 44.91% |
| 2015 Q3 | -1.95 Billion KRW | 0.54% |
| 2015 FY | - KRW | -32.91% |
| 2015 Q1 | -1.44 Billion KRW | 37.11% |
| 2015 Q2 | -1.96 Billion KRW | -36.44% |
| 2014 Q1 | -1.05 Billion KRW | 2.34% |
| 2014 FY | - KRW | -80.97% |
| 2014 Q4 | -2.28 Billion KRW | -168.89% |
| 2014 Q3 | -851.57 Million KRW | 22.55% |
| 2014 Q2 | -1.09 Billion KRW | -3.97% |
| 2013 Q1 | -686.09 Million KRW | 74.4% |
| 2013 Q3 | -1.01 Billion KRW | -42.86% |
| 2013 FY | - KRW | 40.22% |
| 2013 Q2 | -713.34 Million KRW | -3.97% |
| 2013 Q4 | -1.08 Billion KRW | -6.26% |
| 2012 FY | - KRW | 34.9% |
| 2012 Q2 | -1.74 Billion KRW | -1253.64% |
| 2012 Q1 | -129.06 Million KRW | 97.42% |
| 2012 Q4 | -2.68 Billion KRW | -406.59% |
| 2012 Q3 | -529.12 Million KRW | 69.71% |
| 2011 Q2 | -2.56 Billion KRW | -1620.16% |
| 2011 Q4 | -4.99 Billion KRW | -3539.09% |
| 2011 FY | - KRW | -3337.77% |
| 2011 Q1 | 168.66 Million KRW | 114.51% |
| 2011 Q3 | 145.27 Million KRW | 105.67% |
| 2010 Q3 | -638.45 Million KRW | 25.97% |
| 2010 Q2 | -862.47 Million KRW | -130.03% |
| 2010 Q1 | 2.87 Billion KRW | 0.0% |
| 2010 FY | - KRW | -62.07% |
| 2010 Q4 | -1.16 Billion KRW | -82.05% |
| 2009 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Daewoong Co., Ltd. | 248.36 Billion KRW | 108.405% |
| PharmGen Science, Inc. | 13.37 Billion KRW | 256.097% |